Treatment with any investigational agent within 4 weeks prior to cycle 1, day 1, or five drug half-lives (whichever is longer)
Treatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) of enrollment.
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days or five half-lives of the investigational agent, whichever is longer, prior to enrollment
Exposure to an investigational product within 30 days or five half-lives (whichever is the longer) prior to randomization
Participants may not be receiving any other investigational agents; patients previously treated with investigational agents must complete a washout period of at least two weeks or five half-lives, whichever is longer, before starting treatment
Patient who has participated in a prior investigational study within 30 days prior to treatment start or within 5 half-lives of the investigational product, whichever is longer
Participants may not have received treatment with another investigational drug or device within 28 days prior to day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to dosing, whichever may be longer
Investigational therapy (NOTE: or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer).
Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
Participation in a prior investigational study =< 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Received investigational agents within 14 days or 5 half-lives prior to the first study dosing day, whichever is longer
Participation in a prior investigational study within 21 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Participation in another clinical study with an investigational product during the last 30 days or five half-lives of the drug (whichever is greater) prior to the initiation of study treatment
Current enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within 28 days or 5 half lives (whichever is longer) of initiating study treatment.
Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Administration of investigational agents or investigational drugs </=4 weeks or less than (<)5 times the terminal half-life prior to study treatment start, whichever is longer
Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)
Participants who are currently receiving any other investigational agent or have received an investigational agent within 30 days or 5 half-lives prior to study entry, whichever is longer.
Participation in a prior investigational study within 30 days prior to treatment or within 5 half-lives of the investigational product, whichever is longer
Any investigational treatment within 30 days or 5 half-lives, whichever is longer, of Day 1 of treatment
Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Treatment with any investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Participation in another clinical study with an investigational product during the last 2 months or within five half-lives of the compound, whichever is longer
MEDICATION-RELATED: Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer).
Investigational agent within 4 weeks prior to start of study treatment (or within five half-lives of the investigational product, whichever is longer).
Concomitant use of another investigational agent and/or treatment with an investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Participants who are receiving any other investigational agents; patients previously treated with investigational agents must complete a washout period of at least one week or five half-lives, whichever is longer, before starting treatment
Have participated within the past 30 days in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed.
Received active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to Screening
Patients must not have had investigational therapy administered =< 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
Treatment with investigational agent within 4 weeks prior to study treatment (or within five half lives of the investigational product, whichever is longer)
(Atezolizumab-related exclusion) Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)
Participation in any other investigational drug study or had exposure to any other investigational agent, device, or procedure, within 21 days (or 5 half-lives, whichever is greater)
Treatment with any investigational drug within 14 days prior to registration or within 5 half-lives of the investigational product, whichever is longer.
Use of other investigational agent at the time of screening, or within 30 days or five half-lives of screening 1, whichever is longer
Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)
Participation in another clinical study with an investigational product during the last 21 days or 5 half-lives of the investigational product, whichever is longer
Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Participation in a prior investigational interventional study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Received investigational products within 14 days or 5 half-lives of the first study dosing day, whichever is longer
Has received an investigational drug, investigational vaccine, or has used an investigational medical device within 4 weeks or 4 half-lives, whichever is longer, before cycle 1, day 1 of study therapy
Prior therapy with investigational drugs within 28 days or at least 5 half-lives (whichever is longer) before study administration
DONOR: Received any investigational agent within 30 days and/or 5 half-lives (of the other investigational agent), whichever is longer, of receiving BL-8040
Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of study day 1 or within 5 half-lives of the investigational product, whichever is longer, with the exception of a prior cyclin dependent kinase (CDK) 4/6 inhibitor
Participation in a prior investigational therapeutic study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Exposure to an investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation
Treatment with an investigational agent within 28 days of study entry, or 3 half-lives, whichever is longer
Patients who are receiving investigational therapies or who have been treated with investigational therapies or investigational devices within 5 half-lives of the investigational therapy or 4 weeks of first scheduled day of dosing with PFK-158 if the half-live of the investigational agent is not known.
Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within five half-lives of the compound or 3 months, whichever is greater
Subject has received investigational therapy within 28 days or 5 half lives, whichever is longer, prior to screening
Treatment with another investigational drug, biological agent, or device within 6 months of screening, or 5 half-lives of the study agent, whichever is longer.
Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer).
Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Any investigational agent within 14 days or 5 half-lives prior to enrollment, whichever is longer.
participants who are currently receiving any other investigational agent or have received an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to study entry
Treatment with any investigational agent within 30 days (or 5 serum half-lives of the investigational drug, whichever is longer) of enrollment
Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)
Has received investigational agents within 28 days or 5 half-lives (whichever is longer) of Study Day 1
Patient has participated in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
Use of any investigational agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatment
Any investigational agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatment
Participation in a prior investigational study within 30 days prior to enrollment or =< 5 half-lives of the investigational product, whichever is longer
Has received investigational agents within 28 days or 5 half-lives (whichever is longer) of Study Day 1
Exposure to any investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation
Use of other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study treatment.
Exposure to another investigational drug within 42 days of first dosing visit, or 5 half-lives of the study product (whichever is longer)
Concomitant use of another investigational agent and/or treatment with an investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
Any investigational agent =< 28 days or 5 half-lives prior to randomization (whichever is longer)
Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening, and
Subject has received an investigational agent within 4 weeks or 5 half lives whichever is longer prior to Day 1.
Exposure to an investigational product within 30 days or 5 half lives (whichever is longer) prior to start of the current study drug.
Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug
EXPANSION COHORT ONLY: Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug
Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
Exposure to any investigational product (IP) within 30 days or 5 half-lives (whichever is longer) prior to start of study treatment;
Participation in any other clinical study with a potentially therapeutic agent or receipt of another investigational product within 21 days or 5 plasma half-lives, whichever is longer, prior to first day of drug administration (Day 1).
Treatment with investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five half lives of the investigational product, whichever is longer)
Administration of other investigational agents for the treatment of AML/MDS within 21 days (or 5 times the terminal half-life of the investigational treatment whichever is longer) of the start of this trial and throughout the duration of this trial
< 5 half-lives or 14 days, whichever is longer, for any investigational agent (for any indication)
Patients who have received other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study enrollment
Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
Received investigational agents within 14 days or 5 half-lives of the first study dosing day, whichever is longer.
Receipt of any investigational product within 28 days prior to study drug administration or 5 half-lives, whichever is longer.
Use of any investigational agents within 28 days or 5 half-lives (whichever is longer) of treatment
Treatment with another investigational drug or device within 28 days prior to day 1, or if the half-life of the previous product is known, within 5 times the half-life of the investigational drug prior to dosing, whichever is longer
Exposure to investigational drug (including investigational vaccines) or invasive investigational medical device for any indication within 4 weeks or 5 half-lives, whichever is longer, before Cycle 1, Day 1
